233 related articles for article (PubMed ID: 23232984)
1. The potential of recombinant vesicular stomatitis virus-mediated virotherapy against metastatic colon cancer.
Yamaki M; Shinozaki K; Sakaguchi T; Meseck M; Ebert O; Ohdan H; Woo SL
Int J Mol Med; 2013 Feb; 31(2):299-306. PubMed ID: 23232984
[TBL] [Abstract][Full Text] [Related]
2. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
Sung CK; Choi B; Wanna G; Genden EM; Woo SL; Shin EJ
Laryngoscope; 2008 Feb; 118(2):237-42. PubMed ID: 18043494
[TBL] [Abstract][Full Text] [Related]
3. Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.
Chang G; Xu S; Watanabe M; Jayakar HR; Whitt MA; Gingrich JR
J Urol; 2010 Apr; 183(4):1611-8. PubMed ID: 20172545
[TBL] [Abstract][Full Text] [Related]
4. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
5. Treatment of multi-focal colorectal carcinoma metastatic to the liver of immune-competent and syngeneic rats by hepatic artery infusion of oncolytic vesicular stomatitis virus.
Shinozaki K; Ebert O; Woo SL
Int J Cancer; 2005 Apr; 114(4):659-64. PubMed ID: 15609320
[TBL] [Abstract][Full Text] [Related]
6. rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy.
Wu L; Huang TG; Meseck M; Altomonte J; Ebert O; Shinozaki K; García-Sastre A; Fallon J; Mandeli J; Woo SL
Hum Gene Ther; 2008 Jun; 19(6):635-47. PubMed ID: 18533893
[TBL] [Abstract][Full Text] [Related]
7. Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma.
Altomonte J; Marozin S; Schmid RM; Ebert O
Mol Ther; 2010 Feb; 18(2):275-84. PubMed ID: 19809404
[TBL] [Abstract][Full Text] [Related]
8. Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV.
Shinozaki K; Ebert O; Woo SL
Hepatology; 2005 Jan; 41(1):196-203. PubMed ID: 15619242
[TBL] [Abstract][Full Text] [Related]
9. Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus.
Shinozaki K; Ebert O; Kournioti C; Tai YS; Woo SL
Mol Ther; 2004 Mar; 9(3):368-76. PubMed ID: 15006603
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice.
Ebert O; Harbaran S; Shinozaki K; Woo SL
Cancer Gene Ther; 2005 Apr; 12(4):350-8. PubMed ID: 15565179
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats.
Altomonte J; Braren R; Schulz S; Marozin S; Rummeny EJ; Schmid RM; Ebert O
Hepatology; 2008 Dec; 48(6):1864-73. PubMed ID: 19003878
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth.
Kubo T; Shimose S; Matsuo T; Fujimori J; Sakaguchi T; Yamaki M; Shinozaki K; Woo SL; Ochi M
J Orthop Res; 2011 May; 29(5):795-800. PubMed ID: 21437961
[TBL] [Abstract][Full Text] [Related]
13. Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice.
Huang TG; Ebert O; Shinozaki K; García-Sastre A; Woo SL
Mol Ther; 2003 Sep; 8(3):434-40. PubMed ID: 12946316
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
Shin EJ; Wanna GB; Choi B; Aguila D; Ebert O; Genden EM; Woo SL
Laryngoscope; 2007 Feb; 117(2):210-4. PubMed ID: 17204993
[TBL] [Abstract][Full Text] [Related]
15. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus.
Vigil A; Park MS; Martinez O; Chua MA; Xiao S; Cros JF; Martínez-Sobrido L; Woo SL; García-Sastre A
Cancer Res; 2007 Sep; 67(17):8285-92. PubMed ID: 17804743
[TBL] [Abstract][Full Text] [Related]
16. Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells.
Altomonte J; Wu L; Meseck M; Chen L; Ebert O; Garcia-Sastre A; Fallon J; Mandeli J; Woo SL
Cancer Gene Ther; 2009 Mar; 16(3):266-78. PubMed ID: 18846115
[TBL] [Abstract][Full Text] [Related]
17. A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
Cafferata EG; Macció DR; Lopez MV; Viale DL; Carbone C; Mazzolini G; Podhajcer OL
Clin Cancer Res; 2009 May; 15(9):3037-49. PubMed ID: 19336523
[TBL] [Abstract][Full Text] [Related]
18. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
Lun X; Senger DL; Alain T; Oprea A; Parato K; Stojdl D; Lichty B; Power A; Johnston RN; Hamilton M; Parney I; Bell JC; Forsyth PA
J Natl Cancer Inst; 2006 Nov; 98(21):1546-57. PubMed ID: 17077357
[TBL] [Abstract][Full Text] [Related]
19. Metastatic tumor cells detection and anti-metastatic potential with vesicular stomatitis virus in immunocompetent murine model of osteosarcoma.
Johan MP; Kubo T; Furuta T; Sakuda T; Sakaguchi T; Nakanishi M; Ochi M; Adachi N
J Orthop Res; 2018 Sep; 36(9):2562-2569. PubMed ID: 29637599
[TBL] [Abstract][Full Text] [Related]
20. Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer.
Day GL; Bryan ML; Northrup SA; Lyles DS; Westcott MM; Stewart JH
J Surg Res; 2020 Jan; 245():127-135. PubMed ID: 31415934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
